SC-26196 is a potent, orally active inhibitor of Delta6 desaturase (D6D, FADS2). In a rat liver microsome assay, SC-26196 showed an IC50 value of 0.2 µM. SC-26196 has anti-inflammatory properties]1].At a concentration of 200 nM, with treatment for 144 hours, SC-26196 inhibited the proliferation of peripheral blood mononuclear cells (PBMCs), but not Jurkat cells[2].
SC-26196 细胞实验
Cell Line
Concentration
Treated Time
Description
References
NCI-H295R cells
10 μM
18 hours
Analyze mitochondrial lipidome and steroidogenesis
Sci Adv. 2023 Jul 21;9(29):eadf6710
Jurkat T cell leukemia cells
200 nM
144 hours
To investigate the effect of SC26196 on Jurkat cell proliferation. Results showed that SC26196 did not significantly alter Jurkat cell proliferation.
Front Immunol. 2018 Mar 5;9:432
Primary adrenocortical cells
10 μM
18 hours
Measure mitochondrial membrane potential and oxygen consumption rate
Sci Adv. 2023 Jul 21;9(29):eadf6710
SC-26196 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Aged mouse heart model
Oral
100 mg/kg/d
Once daily for 4 weeks
Inhibition of delta-6 desaturase activity, reversal of cardiac phospholipid remodeling, and significant attenuation of cardiac dilatation, hypertrophy, and contractile dysfunction in aged mice
J Gerontol A Biol Sci Med Sci. 2014 Jul;69(7):799-809
SC-26196 动物研究
Animal study
At doses of 0.07, 0.21 or 0.7 mg/kg (up to doses of 0, 10, 30 and 100 mg/kg per day), administered as being added to the feed, SC-26196 caused a decrease in the calculated Δ6-unsaturase index in adipose tissue and liver of male mice. Administration of SC-26196 to male mice at a dose of 100 mg/kg resulted in inhibition of Δ6- desaturase[3].
搜索
